LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia StudyZacks Investment Research • 03/10/25
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS studyPRNewsWire • 03/08/25
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual MeetingBusiness Wire • 03/08/25
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual MeetingBusiness Wire • 02/28/25
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research CollaborationBusiness Wire • 02/20/25
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product SalesZacks Investment Research • 02/10/25
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D MilestonesBusiness Wire • 02/10/25
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 02/05/25
Incyte Gears Up to Report Q4 Earnings: Here's What You Should KnowZacks Investment Research • 02/04/25
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial SizesPRNewsWire • 01/15/25
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/13/25